Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway

Cancer Biology and Therapy

Volumn 14, Issue 12, 2013, Pages 1123-1132

  Wang, Xi ^a   Long, Min ^a   Dong, Ke ^a   Lin, Fang ^a   Weng, Yuanyuan ^a   Ouyang, Yongri ^a   Liu, Li ^a   Wei, Junxia ^a   Chen, Xi ^a   He, Ting ^a   Zhang, Huizhong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

DDP; Immunoresistance; Lung cancer; MAPK; Trop 2

Indexed keywords

ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; SHORT HAIRPIN RNA; TROP 2 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; CISPLATIN; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL SURFACE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

AGED; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MIDDLE AGED;

EID: 84891781279     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.26341     Document Type: Article

References (33)

1. Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 2002; 9:183-95; PMID:12237246; http://dx.doi.org/10.1677/erc.0.0090183 (Pubitemid 35175978)
2. Hilton WM, Ercole B, Parekh DJ, Sonpavde G, Ghosh R, Svatek RS. Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer. Expert Rev Anticancer Ther 2011; 11:949-57; PMID:21707292; http://dx.doi.org/10.1586/era.11.69
3. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005; 5:397-405; PMID:15864281; http://dx.doi.org/ 10.1038/nrc1613
4. Slovin S. Chemotherapy and immunotherapy combination in advanced prostate cancer. Clin Adv Hematol Oncol 2012; 10:90-100; PMID:22402350
5. Recchia F, Candeloro G, Necozione S, Bisegna R, Bratta M, Rea S. Immunotherapy in patients with less than complete response to chemotherapy. Anticancer Res 2009; 29:567-72; PMID:19331204
6. Ripani E, Sacchetti A, Corda D, Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998; 76:671-6; PMID:9610724; http://dx.doi.org/10.1002/(SICI)1097-0215(19980529)76:5〈671:: AID-IJC10〉3.0.CO;2-7 (Pubitemid 28243939)
7. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G, Spizzo G. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008; 99:1290-5; PMID:18813308; http://dx.doi.org/10.1038/sj.bjc.6604677
8. Mühlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, Gastl G, Zitt M, Müller HM, Margreiter R, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 2009; 62:152-8; PMID:18930986; http://dx.doi.org/10.1136/jcp.2008.060590
9. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C, Gerhard S, Rasse M, Laimer K. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 2008; 21:186-91; PMID:18084248 (Pubitemid 351172170)
10. Pak MG, Shin DH, Lee CH, Lee MK. Significance of EpCAM and TROP2 expression in nonsmall cell lung cancer. World J Surg Oncol 2012; 10:53; PMID:22482828; http://dx.doi.org/10.1186/1477-7819-10-53
11. Wu H, Xu H, Zhang S, Wang X, Zhu H, Zhang H, Zhu J, Huang J. Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma. Head Neck 2012; PMID:22987366; http://dx.doi.org/10. 1002/hed.23138
12. Fang YJ, Wang GQ, Lu ZH, Zhang L, Li JB, Wu XJ, Ding PR, Ou QJ, Zhang MF, Jiang W, et al. Different effects of ERβ and TROP2 expression in Chinese patients with early-stage colon cancer. Tumour Biol 2012; 33:2227-35; PMID:23055188; http://dx.doi.org/10.1007/s13277-012-0484-2
13. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006; 12:3057-63; PMID:16707602; http://dx.doi.org/10.1158/1078-0432.CCR-05-1961 (Pubitemid 43837351)
14. Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF, Wan DS. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 2009; 24:875-84; PMID:19421758; http://dx.doi.org/10.1007/s00384-009-0725-z
15. Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem 2011; 59:701-10; PMID:21551320; http://dx.doi.org/10.1369/0022155411410430
16. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci U S A 2008; 105:20882-7; PMID:19088204; http://dx.doi.org/10.1073/pnas.0811411106
17. Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J, Witte ON. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling. Genes Dev 2012; 26:2271-85; PMID:23070813; http://dx.doi.org/10.1101/gad.196451.112
18. El Sewedy T, Fornaro M, Alberti S. Cloning of the murine TROP2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. Int J Cancer 1998; 75:324-30; PMID:9462726; http://dx.doi.org/10.1002/(SICI)1097- 0215(19980119)75:2〈324::AID-IJC24〉3.0.CO;2-B (Pubitemid 28100077)
19. Lü J, Izvolsky KI, Qian J, Cardoso WV. Identification of FGF10 targets in the embryonic lung epithelium during bud morphogenesis. J Biol Chem 2005; 280:4834-41; PMID:15556938; http://dx.doi.org/10.1074/jbc.M410714200 (Pubitemid 40288656)
20. Ripani E, Sacchetti A, Corda D, Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998; 76:671-6; PMID:9610724; http://dx.doi.org/10.1002/(SICI)1097-0215(19980529)76:5〈671:: AID-IJC10〉3.0.CO;2-7 (Pubitemid 28243939)
21. Cubas R, Li M, Chen C, Yao Q. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 2009; 1796:309-14; PMID:19683559
22. Varughese J, Cocco E, Bellone S, de Leon M, Bellone M, Todeschini P, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Uterine serous papillary carcinomas overexpress human trophoblast-cellsurface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Cancer 2011; 117:3163-72; PMID:21246534; http://dx.doi.org/10.1002/ cncr.25891
23. Farivar TN, Najafipour R, Johari P. Nano - drug Delivery of Apoptosis Activator 2 to AGS Cells by Liposomes Conjugated with Anti-TROP2 Antibody. N Am J Med Sci 2012; 4:582-5; PMID:23181231; http://dx.doi.org/10.4103/1947-2714. 103319
24. Yang SH, Sharrocks AD, Whitmarsh AJ. MAP kinase signalling cascades and transcriptional regulation. Gene 2013; 513:1-13; PMID:23123731; http://dx.doi.org/10.1016/j.gene.2012.10.033
25. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410:37-40; PMID:11242034; http://dx.doi.org/10.1038/35065000 (Pubitemid 32225829)
26. Tang Y, Liu F, Zheng C, Sun S, Jiang Y. Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation. J Exp Clin Cancer Res 2012; 31:73; PMID:22967941; http://dx.doi.org/10.1186/1756- 9966-31-73
27. Mayes PA, Degenhardt YY, Wood A, Toporovskya Y, Diskin SJ, Haglund E, Moy C, Wooster R, Maris JM. Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. Int J Cancer 2013; 132:E149-57; PMID:22948716; http://dx.doi.org/10.1002/ijc.27781
28. Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer 2010; 9:253; PMID:20858281; http://dx.doi.org/10.1186/1476-4598-9-253
29. Guerra E, Trerotola M, Aloisi AL, Tripaldi R, Vacca G, La Sorda R, Lattanzio R, Piantelli M, Alberti S. The Trop-2 signalling network in cancer growth. Oncogene 2013; 32:1594-600; PMID:22562244; http://dx.doi.org/10.1038/ onc.2012.151
30. Watanabe M, Miyajima N, Igarashi M, Endo Y, Watanabe N, Sugano S. Sodium phenylacetate inhibits the Ras/MAPK signaling pathway to induce reduction of the c-Raf-1 protein in human and canine breast cancer cells. Breast Cancer Res Treat 2009; 118:281-91; PMID:18953652; http://dx.doi.org/10.1007/s10549-008- 0215-y
31. Jing Y, Liu LZ, Jiang Y, Zhu Y, Guo NL, Barnett J, Rojanasakul Y, Agani F, Jiang BH. Cadmium increases HIF-1 and VEGF expression through ROS, ERK, and AKT signaling pathways and induces malignant transformation of human bronchial epithelial cells. Toxicol Sci 2012; 125:10-9; PMID:21984483; http://dx.doi.org/10.1093/toxsci/kfr256
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63; PMID:6606682; http://dx.doi.org/10.1016/0022-1759(83)90303-4 (Pubitemid 14203433)
33. Zhang P, Sun D, Ke Y, Kaplan HJ, Shao H. The net effect of costimulatory blockers is dependent on the subset and activation status of the autoreactive T cells. J Immunol 2007; 178:474-9; PMID:17182586 (Pubitemid 46033631)